Stock AGN ALGERNON PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Algernon Pharmaceuticals Inc.

Equities

AGN

CA01559R4008

Market Closed - Canadian Securities Exchange
Other stock markets
 19:50:41 10/05/2024 BST 		5-day change 1st Jan Change
0.125 CAD +13.64% Intraday chart for Algernon Pharmaceuticals Inc. +13.64% +92.31%
04-30 Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
04-10 Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug Dmt Stroke Research Program as Its Lead Asset
Algernon Pharmaceuticals Says Acquisition of Ifenprodil Program Completed by US Company
Algernon Pharmaceuticals Inc. acquired 20% stake in Seyltx, Inc.
Algernon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023
Algernon Pharmaceuticals Inc. Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2023
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023
Algernon Pharmaceuticals Engages Maxim Group to Provide Financial Advisory and Investment Banking Services, and to Assist in Identifying and Evaluating Potential M&A and Strategic Opportunities
Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023
Algernon Neuroscience Appoints Dr. David Brody to Advisory Board
Algernon Pharmaceuticals Inc. Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase
Algernon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2022
Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board
Algernon Pharmaceuticals Inc. Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil
Algernon Pharmaceuticals Inc. Forms Private Subsidiary to Advance Company's Psychedelic DMT Stroke Program
Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
Algernon Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AGN Stock
  4. News Algernon Pharmaceuticals Inc.
  5. Other languages